Fox, T;
Booth, C;
Morris, E;
(2021)
Gene Therapy in Cellular Immunodeficiencies.
In:
Cellular Primary Immunodeficiencies.
(pp. 473-497).
Springer
Preview |
Text
Fox_Gene Therapy in Cellular Immunodeficiencies.pdf - Accepted Version Download (487kB) | Preview |
Abstract
The treatment of cellular primary immunodeficiencies has benefitted from significant advances in the field of allogeneic stem cell transplantation (alloHSCT). However, while this therapy is curative for many PIDs, the procedure requires a suitably matched donor and carries significant risks of morbidity and mortality from complications such as graft-versus-host disease (GVHD). Autologous gene therapy (GT) approaches using stem cells isolated from patients and modified ex vivo using viral vectors or gene editing techniques have the potential to offer curative therapy for PID without the immunological complications of alloHSCT. GT for PID has been developed over the last 30 years, and while several setbacks have been encountered along the way, there is now a licensed GT product for ADA-SCID, and promising results from phase I/II clinical trials have demonstrated that GT may offer clinical efficacy comparable to alloHSCT in several other PIDs. Developments in the field are broadening the application of GT, and we expect that this therapeutic modality may become standard of care for the management of several PIDs in the near future. This chapter explores the development of GT over the last 30 years and outlines its role in the management of cellular primary immunodeficiencies.
Archive Staff Only
 |
View Item |
